Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,805 result(s) found for: Carcinoma. Displaying page 43 of 241.
    «« First « Previous 39  40  41  42  43  44  45  46  47  Next» Last»»
    EudraCT Number: 2020-000556-35 Sponsor Protocol Number: D910LC00001 Start Date*: 2020-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected ...
    Medical condition: Completely Resected Stage II-III NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) DK (Prematurely Ended) BG (Completed) HU (Prematurely Ended) DE (Completed) BE (Completed) SE (Prematurely Ended) PL (Completed) CZ (Completed) GR (Completed) IT (Prematurely Ended) FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-003695-35 Sponsor Protocol Number: D4200C00036 Start Date*: 2007-01-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone i...
    Medical condition: Locally-advanced or Metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GR (Ongoing) PT (Completed) IT (Completed) BE (Completed) GB (Completed) ES (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-002925-31 Sponsor Protocol Number: GO41717 Start Date*: 2020-05-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN ...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Prematurely Ended) PL (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005427-16 Sponsor Protocol Number: D4191C00003 Start Date*: 2014-07-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have receive...
    Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10066490 Progression of non-small cell lung cancer LLT
    17.0 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) BE (Trial now transitioned) AT (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000272-34 Sponsor Protocol Number: L00070-IN-214-P1 Start Date*: 2011-08-29
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Phase II study assessing the maintenance treatment with vinflunine after first-line therapy with gemcitabine and cisplatin in patients with advanced or metastatic transitional cell carcinoma of the...
    Medical condition: Advanced or metastatic predominantly transitional cell carcinoma of the urothelial tract.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001249-15 Sponsor Protocol Number: 314-12-401 Start Date*: 2013-11-07
    Sponsor Name:Otsuka Novel Products GmbH
    Full Title: A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive ...
    Medical condition: • Advanced prostate cancer • Advanced epithelial ovarian cancer, advanced squamous cell carcinoma of the cervix, advanced breast cancer, endometrial cancer, and salivary gland cancer that are p...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041848 Squamous cell carcinoma of the cervix PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016853-16 Sponsor Protocol Number: MGN1601-CT1 Start Date*: 2010-08-31
    Sponsor Name:MOLOGEN AG
    Full Title: A Phase I/II, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic ...
    Medical condition: Advanced renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038394 Renal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000989-23 Sponsor Protocol Number: D4881C00024 Start Date*: 2008-07-01
    Sponsor Name:AstraZeneca AB
    Full Title: A ROLLOVER PROTOCOL FOR PATIENTS WHO RECEIVED TREMELIMUMAB (CP-675,206) IN OTHER PROTOCOLS
    Medical condition: Patients who have / have had Melanoma and Other Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007284 Carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005136-34 Sponsor Protocol Number: THIO101 Start Date*: 2022-11-16
    Sponsor Name:MAIA Biotechnology, Inc.
    Full Title: A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001890-27 Sponsor Protocol Number: D4200C00079 Start Date*: 2007-06-15
    Sponsor Name:AstraZeneca SAS
    Full Title: A Randomized, Double Blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with advanced or metastatic papillary or follicular Thyroid Car...
    Medical condition: Advanced or metastatic papillary or follicular Thyroid Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001205 Adenocarcinoma thyroid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DK (Completed) SE (Completed) ES (Ongoing) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005771-12 Sponsor Protocol Number: AIO-KRK-0420 Start Date*: 2022-05-30
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer
    Medical condition: Patients with unresected BRAFV600E mutated/pMMR localized colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001167 Adenocarcinoma of colon PT
    22.0 10022891 - Investigations 10075676 BRAF V600E mutation positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002133-22 Sponsor Protocol Number: C31005 Start Date*: 2016-05-29
    Sponsor Name:Millenium Pharmaceuticals, a wholly owned subsidiary of Takeda pharmaceutical Company Limited
    Full Title: A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advan...
    Medical condition: metastatic clear-cell renal cell carcinoma (mccRCC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038407 Renal cell cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019525-34 Sponsor Protocol Number: MO22923 Start Date*: 2010-12-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA
    Medical condition: EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033128 Ovarian cancer LLT
    12.1 10052204 Ovarian carcinosarcoma LLT
    12.1 10016180 Fallopian tube cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Completed) FR (Completed) ES (Completed) LT (Completed) AT (Completed) LV (Completed) NL (Completed) IE (Completed) SE (Completed) EE (Completed) HU (Completed) IT (Completed) BG (Completed) DK (Completed) SI (Completed) GR (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003399-36 Sponsor Protocol Number: MK-4214-008 Start Date*: 2011-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubi...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003026-69 Sponsor Protocol Number: IO102-IO103-022 Start Date*: 2022-05-09
    Sponsor Name:IO Biotech ApS
    Full Title: A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung ...
    Medical condition: Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046722 Urothelial carcinoma bladder stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000332-40 Sponsor Protocol Number: TTCC-2007-02 Start Date*: 2008-05-21
    Sponsor Name:GRUPO ESPAÑOL DE TRATAMIENTO DE TUMORES DE CABEZA Y CUELLO (TTCC)
    Full Title: ESTUDIO FASE II CON RADIOTERAPIA (RT) CONVENCIONAL + CETUXIMAB PARA EVALUAR LA SUPERVIVENCIA ESPECÍFICA LIBRE DE LARINGECTOMIA TOTAL EN PACIENTES AFECTOS DE UN CARCINOMA ESCAMOSO DE LARINGE LOCALME...
    Medical condition: CARCINOMA ESCAMOSO DE LARINGE LOCALMENTE AVANZADO RESECABLE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007473 Carcinoma squamous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-006790-81 Sponsor Protocol Number: APREC S2007-01 Start Date*: 2008-07-28
    Sponsor Name:APREC
    Full Title: Phase II study of pegylated liposomal doxorubicin (Caelyxâ) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy
    Medical condition: Breast Cancer Patients with Brain Metastases
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic PT
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003673-42 Sponsor Protocol Number: MM-121-01-02-09 Start Date*: 2016-01-19
    Sponsor Name:Merrimack Pharmaceuticals, Inc.
    Full Title: SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Medical condition: Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001077-14 Sponsor Protocol Number: 1200.217 Start Date*: 2014-12-17
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: An open label, single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) har...
    Medical condition: Metastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005887-24 Sponsor Protocol Number: GEMCAD-2103//MO44170 Start Date*: 2022-11-25
    Sponsor Name:Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD)
    Full Title: Phase II study of Atezolizumab plus Tiraglolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal
    Medical condition: Locallized squamous cell carcinoma of the anal canal in the first-line setting.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002141 Anal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 39  40  41  42  43  44  45  46  47  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 10:28:22 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA